AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales. It has several candidates ...

AstraZeneca PLC (LON:AZN – Get Free Report) has been assigned an average rating of “Moderate Buy” from the nine analysts that ...

AstraZeneca (LON:AZN – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at Berenberg Bank in a report issued on Monday, MarketBeat reports. They presently have a GBX 140 ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Olaparib is under clinical development by AstraZeneca and currently in Phase II for Malignant Mesothelioma. According to GlobalData, Phase II drugs for Malignant Mesothelioma have a 42% phase ...

AstraZeneca Plc (NASDAQ:AZN) and Merck & Co Inc (NYSE:MRK), on Wednesday, announced long-term results from the OlympiA Phase 3 trial. The trial showed Lynparza (olaparib) demonstrated sustained ...

Lynparza reduced the risk of death by 28% ... Also Read: After Lung Cancer Approval, AstraZeneca’s Imfinzi Goes Under FDA Priority Review For Bladder Cancer At a median follow-up of 6.1 years ...

--(BUSINESS WIRE)--Updated results from the OlympiA Phase III trial showed AstraZeneca and Merck & Co., Inc’s, known as MSD outside of the US and Canada, LYNPARZA ® (olaparib) demonstrated ...

AstraZeneca (NASDAQ:AZN) and Merck (NYSE:MRK) said long-term data from a Phase 3 study showed that 87.5% of patients treated with their breast cancer drug Lynparza were still alive six years later ...

AstraZeneca Plc (NASDAQ:AZN) and Merck & Co Inc (NYSE:MRK), on Wednesday, announced long-term results from the OlympiA Phase 3 trial. The trial showed Lynparza (olaparib) demonstrated sustained, ...